Meeting
2023 ASCO Genitourinary Cancers Symposium
Atezolizumab with platinum and etoposide chemotherapy followed by cystectomy for patients with localized small cell neuroendocrine bladder cancer.
Authors
Jean H. Hoffman-Censits
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Jean H. Hoffman-Censits , Burles Avner Johnson III, Noah M. Hahn , Woonyoung Choi , Armine Smith , Nirmish Singla , David James McConkey , Max R. Kates
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05312671
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS599)
DOI
10.1200/JCO.2023.41.6_suppl.TPS599
Abstract #
TPS599
Poster Bd #
Q2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trends in treatment patterns associated with small cell lung cancer in a U.S. Medicare population.
First Author: Robert A. Ramirez
First Author: Jue Wang
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto